Compare WLYB & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLYB | TNGX |
|---|---|---|
| Founded | 1807 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Books | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | N/A | N/A |
| Metric | WLYB | TNGX |
|---|---|---|
| Price | $32.30 | $12.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.33 |
| AVG Volume (30 Days) | 2.2K | ★ 2.9M |
| Earning Date | 03-05-2026 | 02-26-2026 |
| Dividend Yield | ★ 4.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.87 | N/A |
| Revenue | ★ $1,665,756,000.00 | $66,501,000.00 |
| Revenue This Year | $0.02 | $52.63 |
| Revenue Next Year | $2.32 | N/A |
| P/E Ratio | $15.52 | ★ N/A |
| Revenue Growth | N/A | ★ 53.29 |
| 52 Week Low | $29.79 | $1.03 |
| 52 Week High | $46.81 | $13.46 |
| Indicator | WLYB | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 46.18 | 60.67 |
| Support Level | $29.79 | $12.17 |
| Resistance Level | $32.65 | $13.18 |
| Average True Range (ATR) | 0.34 | 0.75 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 57.28 | 80.73 |
John Wiley & Sons Inc is a publisher and a trusted leader in research and learning. The company segment includes: Research, which includes the reporting lines of Research Publishing and Research Solutions, and Learning includes the Academic and Professional reporting lines and consists of publishing, courseware, and assessments. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.